Isulgi DND Pharmatech CEO to Highlight 'GLP-1' Expansion Potential at BIX2024

DND Pharmatech, a company specializing in the development of glucagon-like peptide (GLP)-1 based new drugs, announced on the 4th that CEO Seulgi Lee has been invited as a speaker at 'BioPlus-InterPhex Korea 2024 (BIX2024)' to give a presentation on the topic of ‘GLP-1 based new drugs.’

Hosted by the Korea Bio Association and organized by Reed Exhibitions Korea (RX Korea), this event is the largest comprehensive bio and pharmaceutical convention in Korea, with participation from 250 companies across 15 countries. It will be held for three days from the 10th to the 12th at COEX in Gangnam-gu, Seoul.

CEO Seulgi Lee will deliver presentations on two topics over two days, the 10th and 11th, at BIX2024: ‘GLP-1: Trends in Expanding Indications in the Obesity Treatment Market’ and ‘Innovation and Investment Opportunities in Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Multifaceted Approach.’

The first presentation, titled ‘GLP-1, a New Hope for Degenerative Brain Diseases,’ will discuss the potential of GLP-1 drugs to extend beyond diabetes and obesity treatment into various fields such as degenerative brain diseases. Since GLP-1 based drugs were first developed as diabetes treatments, their applicability has expanded to obesity, MASH, cardiovascular diseases, and various metabolic disorders. Notably, recent discoveries of the mechanism by which GLP-1 drugs target microglia to block neuroinflammatory responses have led to active clinical development for degenerative brain diseases such as Parkinson’s disease and Alzheimer’s disease.

The second presentation, under the theme ‘Innovative Development Strategies for Effective MASH Treatment,’ will explain the global development strategies and competitive landscape of multi-acting agents targeting GLP-1 along with glucagon and glucose-dependent insulinotropic polypeptide (GIP) for MASH treatment. DND Pharmatech’s MASH treatment candidate, DD01, is being developed as a dual agonist targeting both GLP-1 and glucagon. In June, it received approval for a Phase 2 clinical trial and has begun clinical testing in MASH patients with obesity.

Seulgi Lee, CEO of DND Pharmatech, said, “It is an honor to present on GLP-1 at this year’s BIX2024,” adding, “We feel the strong market interest in GLP-1, and through this presentation, we aim to widely promote DND Pharmatech’s GLP-1 technology and the value of our pipeline.”